Lucian Ionescu

Dual IL-17A and IL-17F neutralisation by bimekizumab in psoriatic arthritis: evidence from preclinical experiments and a randomised placebo-controlled clinical trial that IL-17F contributes to human chronic tissue inflammation

Sophie Glatt, Dominique Baeten, Terry Baker et al. · Annals of the Rheumatic Diseases · 2017 · 259 citations · Full text

Medicine, Immunology, Pharmacology +17

Head-to-head comparison of certolizumab pegol versus adalimumab in rheumatoid arthritis: 2-year efficacy and safety results from the randomised EXXELERATE study

Josef S Smolen, Gerd‐Rüdiger Burmester, Bernard Combe et al. · The Lancet · 2016 · 180 citations

Life Sciences, Clinical Sciences, Immunology +11

Efficacy and Safety of Bimekizumab in Moderate to Severe Hidradenitis Suppurativa

Sophie Glatt, Gregor B. E. Jemec, Seth Forman et al. · JAMA Dermatology · 2021 · 167 citations · Full text

Pharmacy, Internal Medicine, Pharmacotherapy +16

Timing and Magnitude of Initial Change in Disease Activity Score 28 Predicts the Likelihood of Achieving Low Disease Activity at 1 Year in Rheumatoid Arthritis Patients Treated with Certolizumab Pegol: A Post-hoc Analysis of the RAPID 1 Trial

Désirée van der Heijde, Edward Keystone, Jeffrey R. Curtis et al. · The Journal of Rheumatology · 2012 · 73 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +15

Efficacy and safety of bimekizumab as add-on therapy for rheumatoid arthritis in patients with inadequate response to certolizumab pegol: a proof-of-concept study

Sophie Glatt, Peter C. Taylor, Iain B. McInnes et al. · Annals of the Rheumatic Diseases · 2019 · 55 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +16